Acrux Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Acrux hat ein Gesamteigenkapital von A$5.6M und eine Gesamtverschuldung von A$0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen A$12.0M bzw. A$6.4M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

AU$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	AU$4.57m
Eigenkapital	AU$5.64m
Gesamtverbindlichkeiten	AU$6.38m
Gesamtvermögen	AU$12.02m

Jüngste Berichte zur Finanzlage

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Sep 21

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

May 20

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Feb 04

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Dec 14

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ACRDie kurzfristigen Aktiva des Unternehmens (A$9.2M) übersteigen seine kurzfristigen Passiva (A$4.4M).

Langfristige Verbindlichkeiten: ACRDie kurzfristigen Vermögenswerte des Unternehmens (A$9.2M) übersteigen seine langfristigen Verbindlichkeiten (A$2.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ACR ist schuldenfrei.

Schulden abbauen: ACR hat in den letzten 5 Jahren keine Schulden gemacht.

Schuldendeckung: ACR hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: ACR hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Acrux Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Recent updates

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen